-
Mashup Score: 71Relationship Between Exercise-Induced Cardiac Troponin Elevations and Occult Coronary Atherosclerosis in Middle-Aged Athletes: - 29 day(s) ago
AbstractBackgroundExercise increases cardiac troponin (cTn) concentrations with significant heterogeneity across individuals.ObjectivesThis study compared the prevalence and magnitude of coronary a…
Source: www.jacc.orgCategories: General Medicine NewsTweet
-
Mashup Score: 70Relationship Between Exercise-Induced Cardiac Troponin Elevations and Occult Coronary Atherosclerosis in Middle-Aged Athletes: - 1 month(s) ago
AbstractBackgroundExercise increases cardiac troponin (cTn) concentrations with significant heterogeneity across individuals.ObjectivesThis study compared the prevalence and magnitude of coronary a…
Source: www.jacc.orgCategories: General Medicine NewsTweet-
Now in @JACCJournals, @ThijsEijsvogels and colleagues find that most exercise induced troponin elevation is not explainable by CAD. https://t.co/DXwb841eIf @MeaganWasfy and I contextualize these results in accompanying editorial @MGHHeartHealth https://t.co/YOM01UBQdv https://t.co/kzaGgbO6Da
-
-
Mashup Score: 70Relationship Between Exercise-Induced Cardiac Troponin Elevations and Occult Coronary Atherosclerosis in Middle-Aged Athletes: - 1 month(s) ago
AbstractBackgroundExercise increases cardiac troponin (cTn) concentrations with significant heterogeneity across individuals.ObjectivesThis study compared the prevalence and magnitude of coronary a…
Source: www.jacc.orgCategories: General Medicine NewsTweet-
Now in @JACCJournals, @ThijsEijsvogels and colleagues find that most exercise induced troponin elevation is not explainable by CAD. https://t.co/DXwb841eIf @MeaganWasfy and I contextualize these results in accompanying editorial @MGHHeartHealth https://t.co/YOM01UBQdv https://t.co/kzaGgbO6Da
-
-
Mashup Score: 24
This Viewpoint describes the benefits and barriers of conducting cardiovascular disease outcome trials to provide evidence of effectiveness of novel blood pressure (BP)–lowering therapies in reducing hypertension.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
After 20 years of static development, 3 novel BP ⬇️ therapies were FDA approved in 2024. Now in @JAMACardio, led by ⭐️ @UMassChan student Ritika Revoori, we discuss whether BP surrogate endpoint trials are sufficient for endorsement. @johnwmcevoy https://t.co/gNCiv7qEnI
-
-
Mashup Score: 45Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis - 3 month(s) ago
AbstractBackgroundThe extent to which high-sensitivity cardiac troponin can predict cardiovascular disease (CVD) is uncertain.ObjectivesWe aimed to quantify the potential advantage of adding inform…
Source: www.jacc.orgCategories: General Medicine NewsTweet-
In this weeks edition of @JACCJournals, Dr. Shah and colleagues explore the use of hs-cTn in CVD risk prediction for primary prevention. https://t.co/c8lYoIW9xB Drs. Januzzi, @johnwmcevoy, and I discuss the implication of their findings. https://t.co/aCWHyYcrVo https://t.co/piELQtALWv
-
-
Mashup Score: 0Utilization of Cardiovascular Procedures, Consultation Services, and Cardioprotective Medications Among Type 2 Myocardial Infarction Patients: - 5 month(s) ago
AbstractBackgroundCoronary atherosclerosis and recurrent cardiovascular events are common among individuals with type 2 myocardial infarction (T2MI). However, cardiovascular resource utilization am…
Source: www.jacc.orgCategories: General Medicine News, CardiologistsTweet-
Our paper lead by Drs. Harsh Goel and Adwait Mehta evaluating use of cardiac testing and secondary preventative therapies among T2MI patients across U.S. @JACCJournals #JACCADV @JJheart_doc @MGHHeartHealth 1/ https://t.co/2UJXQ2xiVP https://t.co/GZuAzyIKhN
-
-
Mashup Score: 13High-Sensitivity Cardiac Troponin Assays: From Implementation to Resource Utilization and Cost Effectiveness - 5 month(s) ago
AbstractBackground. Cardiac troponin is the gold-standard biomarker for the evaluation of patients with suspected acute myocardial infarction (MI). Improve
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet-
Led by Dr. Hong-Kee Lee, we review the implementation of hs-cTn assays including practical suggestions @JJheart_doc @richardbody @yadersandoval High-Sensitivity Cardiac Troponin Assays: From Implementation to Resource Utilization and Cost Effectiveness https://t.co/VFOvRDXrV0
-
-
Mashup Score: 5Inconsistent Troponin Testing in US EDs Warrants Closer Look - 6 month(s) ago
New data from US centers suggest some overtesting in patients without chest pain, and undertesting in those who do.
Source: www.tctmd.comCategories: General Medicine News, CardiologistsTweet-
Inconsistent Troponin Testing in US EDs Warrants Closer Look https://t.co/kiUykXIjTB
-
-
Mashup Score: 46Cardiac Biomarker Testing in US Emergency Departments - 6 month(s) ago
This cross-sectional study identifies variables in cardiac biomarker testing and their association with acute coronary syndrome incidence among adults visiting the emergency department.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet-
Now out in @JAMAInternalMed, @Nate_Watson8, @jasonwasfy, @JJheart_doc, and @EricSecemskyMD pose the question - how often do individuals presenting to the ED undergo cardiac biomarker testing for MI? @MGHHeartHealth 1/ https://t.co/ttEPAXfpd6
-
-
Mashup Score: 23
In 2024, the European Society of Cardiology released a new guideline for the management of elevated blood pressure (BP) and hypertension. The guideline introduced a new BP categorization: (1) nonelevated (office BP <120/70 mm Hg) for which drug treatment is not recommended, (2) elevated (120–139/70–89 mm Hg) for which drug treatment is recommended based on cardiovascular disease risk and follow-up BP level, and (3) hypertension (≥140/90 mm Hg) for which prompt confirmation and drug treatment are recommended in all individuals. The initial default systolic BP treatment target is 120 to 129 mm Hg for most; however, relaxed targets (BP as low as reasonably achievable) are recommended in case of treatment intolerance, adults ≥85 years, symptomatic orthostasis, moderate-to-severe frailty, or limited life expectancy. Here, we summarize what is new and different in the 2024 European Society of Cardiology guidelines, relative to other major international hypertension guidelines in Europe and A
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Now in @HyperAHA, @rosam_bruno @kazemr @LabTouyz and @johnwmcevoy discuss what is new and different in the 2024 ESC Hypertension guideline compared to the 2017 ACC/AHA and 2023 ESH Hypertension guidelines https://t.co/1I7SUziykl 1/
-
Now in @JACCJournals, @ThijsEijsvogels and colleagues find that most exercise induced troponin elevation is not explainable by CAD. https://t.co/DXwb841eIf @MeaganWasfy and I contextualize these results in accompanying editorial @MGHHeartHealth https://t.co/YOM01UBQdv https://t.co/kzaGgbO6Da